Thyroid cancer: Molecular aspects and new therapeutic strategies

Journal of Thyroid Research

Volumn 2012, Issue , 2012, Pages

  Grande, Enrique ^a   Díez, Juan José ^a   Zafon, Carles ^b   Capdevila, Jaume ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; B RAF KINASE; CABOZANTINIB; CARBOPLATIN; COMBRETASTATIN A4 PHOSPHATE; DOXORUBICIN; GEMCITABINE; LENVATINIB; LEVOTHYROXINE; MITOGEN ACTIVATED PROTEIN KINASE; MOTESANIB; NAVELBINE; PACLITAXEL; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN PATCHED; PROTEIN RET; RADIOACTIVE IODINE; RAF PROTEIN; RAS PROTEIN; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TAXANE DERIVATIVE; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ALOPECIA; ANOREXIA; ASTHENIA; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; DIARRHEA; DIFFERENTIATED THYROID CANCER; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; GENE MUTATION; GENE REARRANGEMENT; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); NAUSEA; NEUTROPENIA; ONCOGENE; ONCOGENE MEK; ONCOGENE RAF; ONCOGENE RAS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RADIOISOTOPE THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RET GENE; REVIEW; SIDE EFFECT; THORAX PAIN; THROMBOCYTOPENIA; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

EID: 84869019637     PISSN: 20908067     EISSN: 20420072     Source Type: Journal    
DOI: 10.1155/2012/847108     Document Type: Review

References (40)

1. Asioli S., Erickson L. A., Righi A., Jin L., Volante M., Jenkins S., Papotti M., Bussolati G., Lloyd R. V., Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Modern Pathology 2010 23 9 1269 1278 2-s2.0-77956294580 10.1038/modpathol.2010. 117
2. Chen A. Y., Jemal A., Ward E. M., Increasing incidence of differentiated thyroid cancer in the United States, 19882005. Cancer 2009 115 16 3801 3807 2-s2.0-68549099879 10.1002/cncr.24416
3. Enewold L., Zhu K., Ron E., Marrogi A. J., Stojadinovic A., Peoples G. E., Devesa S. S., Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 19802005. Cancer Epidemiology Biomarkers and Prevention 2009 18 3 784 791 2-s2.0-64549114616 10.1158/1055-9965.EPI-08- 0960
4. Shimaoka K., Schoenfeld D. A., DeWys W. D., A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985 56 9 2155 2160 2-s2.0-0022355480 (Pubitemid 16236586)
5. Kondo T., Ezzat S., Asa S. L., Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Reviews Cancer 2006 6 4 292 306 2-s2.0-33645307434 10.1038/nrc1836
6. Sipos J. A., Shah M. H., Thyroid cancer: emerging role for targeted therapies. Therapeutic Advances in Medical Oncology 2010 2 1 3 16 2-s2.0-77953368220 10.1177/1758834009352667
7. Soh E. Y., Eigelberger M. S., Kim K. J., Wong M. G., Young D. M., Clark O. H., Duh Q. Y., Farndon J., Demeure M., Roeher H. D., Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo. Surgery 2000 128 6 1059 1066 2-s2.0-0033671622
8. Yu X. M., Lo C. Y., Chan W. F., Lam K. Y., Leung P., Luk J. M., Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clinical Cancer Research 2005 11 22 8063 8069 2-s2.0-28144454205 10.1158/1078-0432.CCR-05-0646 (Pubitemid 41698749)
9. Haq M. S., McCready R. V., Harmer C. L., Treatment of advanced differentiated thyroid carcinoma with high activity radioiodine therapy. Nuclear Medicine Communications 2004 25 8 799 805 2-s2.0-4143094738 10.1097/01.mnm.0000136693.94761.5c (Pubitemid 39099992)
10. Schlumberge M., Sherman S., Approach to the patient with advanced differentiated thyroid cancer. European Journal of Endocrinology 2011 166 1 5 11
11. Matuszczyk A., Petersenn S., Bockisch A., Gorges R., Sheu S. Y., Veit P., Mann K., Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Hormone and Metabolic Research 2008 40 3 210 213 2-s2.0-43249107532 10.1055/s-2008-1046781 (Pubitemid 351690526)
12. Licitra L., Locati L. D., Greco A., Granata R., Bossi P., Multikinase inhibitors in thyroid cancer. European Journal of Cancer 2010 46 6 1012 1018 2-s2.0-77949539631 10.1016/j.ejca.2010.01.010
13. De Souza E. C. L., Ferreira A. C., De Carvalho D. P., The mTOR protein as a target in thyroid cancer. Expert Opinion on Therapeutic Targets 2011 15 9 1099 1112 10.1517/14728222.2011.594044
14. Marotta V., Guerra A., Sapio M. R., Vitale M., RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint. European Journal of Endocrinology 2011 165 4 499 507 10.1530/EJE-11-0499
15. Bounacer A., Schlumberger M., Wicker R., Du-Villard J. A., Caillou B., Sarasin A., Suárez H. G., Search for NTRK1 proto-oncogene rearrangements in human thyroid tumours originated after therapeutic radiation. British Journal of Cancer 2000 82 2 308 314 2-s2.0-0033954244 (Pubitemid 30045375)
16. Gupta-Abramson V., Troxel A. B., Nellore A., Puttaswamy K., Redlinger M., Ransone K., Mandel S. J., Flaherty K. T., Loevner L. A., O'Dwyer P. J., Brose M. S., Phase II trial of sorafenib in advanced thyroid cancer. Journal of Clinical Oncology 2008 26 29 4714 4719 2-s2.0-50649095250 10.1200/JCO.2008.16. 3279
17. Kloos R. T., Ringel M. D., Knopp M. V., Hall N. C., King M., Stevens R., Liang J., Wakely P. E., Vasko V. V., Saji M., Rittenberry J., Wei L., Arbogast D., Collamore M., Wright J. J., Grever M., Phase II trial of sorafenib in metastatic thyroid cancer. Journal of Clinical Oncology 2009 27 10 1675 1684 2-s2.0-63849265332 10.1200/JCO.2008.18.2717
18. Ahmed M., Barbachano Y., Riddell A., Hickey J., Newbold K. L., Viros A., Harrington K. J., Marais R., Nutting C. M., Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. European Journal of Endocrinology 2011 165 2 315 322 2-s2.0-79960179069 10.1530/EJE-11-0129
19. Hoftijzer H., Heemstra K. A., Morreau H., Stokkel M. P., Corssmit E. P., Gelderblom H., Weijers K., Pereira A. M., Huijberts M., Kapiteijn E., Romijn J. A., Smit J. W., Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. European Journal of Endocrinology 2009 161 6 923 931 2-s2.0-72949106263 10.1530/EJE-09-0702
20. Capdevila J., Iglesias L., Halperin I., Segura Á., Martínez-Trufero J., Vaz M. Á., Corral J., Obiols G., Grande E., Grau J. J., Tabernero J., Sorafenib in metastatic thyroid cancer. Endocrine-Related Cancer 2012 19 2 209 216 10.1530/ERC-11-0351
21. Leboulleux S., Bastholt L., Krause T. M., Vandetanib in locally advanced or metastatic differentiated thyroid cancer (papillary or follicular; DTC): a randomized, double-blind phase II trial. Proceedings of the 4th International Thyroid Congress 2010 Paris, France Abstract OC-023
22. Cohen E. E. W., Rosen L. S., Vokes E. E., Kies M. S., Forastiere A. A., Worden F. P., Kane M. A., Sherman E., Kim S., Bycott P., Tortorici M., Shalinsky D. R., Liau K. F., Cohen R. B., Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. Journal of Clinical Oncology 2008 26 29 4708 4713 2-s2.0-50649095801 10.1200/JCO.2007.15.9566
23. Carr L. L., Mankoff D. A., Goulart B. H., Eaton K. D., Capell P. T., Kell E. M., Bauman J. E., Martins R. G., Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clinical Cancer Research 2010 16 21 5260 5268 2-s2.0-78049462514 10.1158/1078-0432.CCR-10-0994
24. Cohen E. E., Needles B. M., Cullen K. J., Phase 2 study of sunitinib in refractory thyroid cancer. Journal of Clinical Oncology 2008 26 supplement, abstract 6025
25. Sherman S. I., Jarzab B., Cabanillas M. E., A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). Journal of Clinical Oncology 2011 29 supplement, abstract 5503
26. Sherman S. I., Wirth L. J., Droz J. P., Hofmann M., Bastholt L., Martins R. G., Licitra L., Eschenberg M. J., Sun Y. N., Juan T., Stepan D. E., Schlumberger M. J., Motesanib diphosphate in progressive differentiated thyroid cancer. New England Journal of Medicine 2008 359 1 31 42 2-s2.0-46449117698 10.1056/NEJMoa075853 (Pubitemid 351931094)
27. Bible K. C., Suman V. J., Molina J. R., Smallridge R. C., Maples W. J., Menefee M. E., Rubin J., Sideras K., Morris J. C., McIver B., Burton J. K., Webster K. P., Bieber C., Traynor A. M., Flynn P. J., Goh B. C., Tang H., Ivy S. P., Erlichman C., Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. The Lancet Oncology 2010 11 10 962 972 2-s2.0-77957359933 10.1016/S1470-2045(10)70203-5
28. Wells S. A. Jr., Robinson B. G., Gagel R. F., Dralle H., Fagin J. A., Santoro M., Baudin E., Elisei R., Jarzab B., Vasselli J. R., Read J., Langmuir P., Ryan A. J., Schlumberger M. J., Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. Journal of Clinical Oncology 2012 30 2 134 141 10.1200/JCO.2011.35.5040
29. Kurzrock R., Sherman S. I., Ball D. W., Forastiere A. A., Cohen R. B., Mehra R., Pfister D. G., Cohen E. E. W., Janisch L., Nauling F., Hong D. S., Ng C. S., Ye L., Gagel R. F., Frye J., Müller T., Ratain M. J., Salgia R., Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. Journal of Clinical Oncology 2011 29 19 2660 2666 2-s2.0-79959936054 10.1200/JCO.2010.32.4145
30. Lam E. T., Ringel M. D., Kloos R. T., Prior T. W., Knopp M. V., Liang J., Sammet S., Hall N. C., Wakely P. E., Vasko V. V., Saji M., Snyder P. J., Wei L., Arbogast D., Collamore M., Wright J. J., Moley J. F., Villalona-Calero M. A., Shah M. H., Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. Journal of Clinical Oncology 2010 28 14 2323 2330 2-s2.0-77952468875 10.1200/JCO.2009.25.0068
31. Schlumberger M. J., Elisei R., Bastholt L., Wirth L. J., Martins R. G., Locati L. D., Jarzab B., Pacini F., Daumerie C., Droz J. P., Eschenberg M. J., Sun Y. N., Juan T., Stepan D. E., Sherman S. I., Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. Journal of Clinical Oncology 2009 27 23 3794 3801 2-s2.0-68949108390 10.1200/JCO.2008.18.7815
32. De Souza J. A., Busaidy N., Zimrin A., Phase II trial of sunitinib in medullary thyroid cancer (MTC). Journal of Clinical Oncology 2010 28 15s supplement, abstract 5504
33. Santarpia L., Myers J. N., Sherman S. I., Trimarchi F., Clayman G. L., El-Naggar A. K., Genetic alterations in the Ras/Raf/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Cancer 2010 116 12 2974 2983 2-s2.0-77954022714 10.1002/cncr.25061
34. Grande-Pulido E., Castelo B., Fonseca P. J., Efficacy and tolerability of sunitinib in patients with advanced thyroid cancer out of a trial: a Spanish multicenter cohort. Journal of Clinical Oncology 2011 29 supplement, abstract e16024
35. Cakir M., Grossman A. B., Medullary thyroid cancer: molecular biology and novel molecular therapies. Neuroendocrinology 2009 90 4 323 348 2-s2.0-71849111319 10.1159/000220827
36. Pacini F., Castagna M. G., Cipri C., Schlumberger M., Medullary thyroid carcinoma. Clinical Oncology 2010 22 6 475 485 2-s2.0-77954757206 10.1016/j.clon.2010.05.002
37. Phay J. E., Shah M. H., Targeting RET receptor tyrosine kinase activation in cancer. Clinical Cancer Research 2010 16 24 5936 5941 2-s2.0-78650412305 10.1158/1078-0432.CCR-09-0786
38. Perri F., Lorenzo G. D., Scarpati G. D., Buonerba C C., Anaplastic thyroid carcinoma: a comprehensive review of current and future therapeutic options. World Journal of Clinical Oncology 2011 2 3 150 157
39. Nagaiah G., Fu P., Wasman J. K., CTRU Research Nurses. Phase II trial of sorafenib (bay 43-9006) in patients with advanced anaplastic carcinoma of the thyroid. Journal of Clinical Oncology 2009 27 15s supplement, abstract 6058
40. Sosa J. A., Elisei R., Jarzab B., A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): final survival analysis for the FACT trial. Journal of Clinical Oncology 2011 29 supplement, abstract 5502